US4332787A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Assay for beta-adrenergic antagonists and antibody therefor
Assignee: General Hospital Corp
•
Filing: 1980-06-23
•
Granted: 1982-06-01
•
Expires: 2000-06-23
Abstract
Abstract Body fluids are assayed for aryloxypropylamine beta-adrenergic antagonists and/or their active metabolites by agglutination reaction with antibody for the antagonist and/or active metabolite. The antibody is produced from an antigen comprising a conjugate of an immunogenic protein linked by a diazo moiety to an aryloxypropylamine beta-adrenergic antagonist.
Inventors
- 👤 Charles J. Homcy
- 👤 Edgar Haber
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-31 15:20
CPC Classifications
G; G01; G01N; G01N33/00; G01N33/48; G01N33/50; G01N33/94; G01N33/9453; Y; Y10; Y10S; Y10S436/00; Y10S436/804; Y10S436/823
Claims Analysis
Total Claims: 16
Claim 1
Independent Claim
124 words
The process for determining the concentration of a material selected from the group consisting of an aryloxypropylamine beta-adrenergic antagonist or an active metabolite of said antagonist and mixtures thereof in a sample which comprises: a. mixing the sample with an antibody for said material, said antibody being formed from an antigen comprising a conjugate of an immunogenic protein linked by a diazo moiety to (a) an aryloxypropylamine beta-adrenergic antagonist or (b) a derivative of said antagonist having beta-adrenergic activity which derivative includes an aryloxypropylamine moiety, b. determining the extent of the binding reaction between said antibody and said material, and, c. comparing the measured extent of binding of an unknown with a known quantitative relationship between extent of binding and concentration of said material.
Claim 2
Dependent Claim
124 words
The process for determining the concentration of a material selected from the group consisting of an aryloxypropylamine beta-adrenergic antagonist or an active metabolite of said antagonist and mixtures thereof in a sample which comprises: a. mixing the sample with an antibody for said material, said antibody being formed from an antigen comprising a conjugate of an immunogenic protein linked by a diazo moiety to (a) an aryloxypropylamine beta-adrenergic antagonist or (b) a derivative of said antagonist having beta-adrenergic activity which derivative includes an aryloxypropylamine moiety, b. determining the extent of the binding reaction between said antibody and said material, and, c. comparing the measured extent of binding of an unknown with a known quantitative relationship between extent of binding and concentration of said material.
Claim 3
Dependent Claim
43 words
The process of claim 1 wherein said binding reaction is effected by mixing a sample of said material labeled with a radioactive isotope with said antibody to effect binding of said material with said antibody and separating said material bound to said antibody.
Claim 4
Dependent Claim
71 words
The process of claim 1 wherein said agglutination reaction is effected by mixing a sample of said material with a known concentration of said antibody, said concentration being in excess of that required for complete reaction of said material thereby to form a composition containing unreacted antibody, reacting said composition with said material labeled with a radioactive isotope and determining the extent of agglutination between said composition and said labeled material.
Claim 5
Dependent Claim
19 words
The process of claim 2 wherein said radioactive isotope is selected from the group consisting of tritium and iodine.
Claim 6
Dependent Claim
19 words
The process of claim 3 wherein said radioactive isotope is selected from the group consisting of tritium and iodine.
Claim 7
Dependent Claim
28 words
The process of any one of claims 1, 2, 3, 4 or 5 wherein said antigen is acebutolol amine linked to an immunogenic protein through a diazo moiety.
Claim 8
Dependent Claim
28 words
The process of any one of claims 1, 2, 3, 4 or 5 wherein said antigen is hydroxybenzyl propranolol linked to an immunogenic protein through a diazo moiety.
Claim 9
Dependent Claim
28 words
The process of any one of claims 1, 2, 3, 4 or 5 wherein said antigen is hydroxybenzyl pindolol linked to an immunogenic protein through a diazo moiety.
Claim 10
Dependent Claim
72 words
An antibody produced by incubating in the serum of an animal an antigen comprising a conjugate of an immunogenic protein linked by a diazo moiety to (a) an aryloxypropylamine beta-antagonist or (b) a derivative of said antagonist having beta-adrenergic activity which derivative includes an aryloxypropylamine moiety and recovering said antibody from said serum, said antibody being reactive with an aryloxypropylamine beta-adrenergic antagonist or a metabolite of said antagonist having beta-adrenergic antagonist activity.
Claim 11
Dependent Claim
72 words
An antibody produced by incubating in the serum of an animal an antigen comprising a conjugate of an immunogenic protein linked by a diazo moiety to (a) an aryloxypropylamine beta-antagonist or (b) a derivative of said antagonist having beta-adrenergic activity which derivative includes an aryloxypropylamine moiety and recovering said antibody from said serum, said antibody being reactive with an aryloxypropylamine beta-adrenergic antagonist or a metabolite of said antagonist having beta-adrenergic antagonist activity.
Claim 12
Dependent Claim
14 words
The antibody of claim 9 wherein said immunogenic protein is linked to acebutolol amine.
Claim 13
Dependent Claim
14 words
The antibody of claim 9 wherein said immunogenic protein is linked to hydroxybenzyl pindolol.
Claim 14
Dependent Claim
14 words
The antibody of claim 9 wherein said immunogenic protein is linked to hydroxybenzyl propranolol.
Claim 15
Dependent Claim
20 words
The antibody of any one of claims 9, 10, 11 or 12 wherein said immunogenic protein is blood serum albumin.
Claim 16
Dependent Claim
18 words
The antibody of any one of claims 9, 10, 11 or 12 wherein said immunogenic protein is hemocyanin.
References Cited (Backward Citations)
US4026879A
Cited
US4070492A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1985-05-31 | 1985-11-30 | 1986-06-01 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1989-05-31 | 1989-11-30 | 1990-06-01 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1993-05-31 | 1993-11-30 | 1994-06-01 | $7700.00 | Window Closed / Lapsed |